DNDi announces new Director of Neglected Tropical Diseases

Former DNDi Medical Director Dr Nathalie Strub-Wourgaft takes over leadership of NTD programme

DNDi is pleased to announce the appointment of Dr Nathalie Strub-Wourgaft as the new Director of Neglected Tropical Diseases. She will assume her new role as NTD Director and member of DNDi’s Executive Team as of 1 July 2018.

R&D Portfolio Update March 2018: DNDi Sleeping sickness programme

Phase II/III study results confirmed that fexinidazole, DNDi’s first new chemical entity is safe and effective, and presents significant advantages over current treatment as it removes the need for lumbar puncture and systematic patient hospitalization. A regulatory dossier has been submitted to the European Medicines Agency for fexinidazole as the first all-oral treatment for sleeping sickness.

ECTMIH 2017

October 16-20, 2017
Antwerp, Belgium
DNDi presented on sleeping sickness, visceral leishmaniasis, mycetoma, and onchocerciasis.

World Health Summit 2017

October 15-17, 2017
Berlin, Germany
Monique Wasunna, Director of DNDi Africa, presented on strengthening capacity for visceral leishmaniasis clinical research in Africa.

Celgene joins DNDi’s ‘Drug Discovery Booster’ to accelerate discovery of new treatments for neglected diseases

[Summit, New Jersey and Geneva, Switzerland – June 15, 2016]
First US-based biopharmaceutical partner to join global consortium
The biopharmaceutical company Celgene has become the fifth company to join the “Neglected Tropical Diseases Drug Discovery Booster” consortium, a new initiative to accelerate and cut the cost of early stage drug discovery for two of the world’s most neglected diseases, leishmaniasis and Chagas disease.